欢迎来到麦多课文档分享! | 帮助中心 海量文档,免费浏览,给你所需,享你所想!
麦多课文档分享
全部分类
  • 标准规范>
  • 教学课件>
  • 考试资料>
  • 办公文档>
  • 学术论文>
  • 行业资料>
  • 易语言源码>
  • ImageVerifierCode 换一换
    首页 麦多课文档分享 > 资源分类 > PDF文档下载
    分享到微信 分享到微博 分享到QQ空间

    ASTM E2474-2006 Standard Practice for Pharmaceutical Process Design Utilizing Process Analytical Technology《利用过程分析技术进行制药过程设计的标准规程》.pdf

    • 资源ID:531210       资源大小:53.70KB        全文页数:3页
    • 资源格式: PDF        下载积分:5000积分
    快捷下载 游客一键下载
    账号登录下载
    微信登录下载
    二维码
    微信扫一扫登录
    下载资源需要5000积分(如需开发票,请勿充值!)
    邮箱/手机:
    温馨提示:
    如需开发票,请勿充值!快捷下载时,用户名和密码都是您填写的邮箱或者手机号,方便查询和重复下载(系统自动生成)。
    如需开发票,请勿充值!如填写123,账号就是123,密码也是123。
    支付方式: 支付宝扫码支付    微信扫码支付   
    验证码:   换一换

    加入VIP,交流精品资源
     
    账号:
    密码:
    验证码:   换一换
      忘记密码?
        
    友情提示
    2、PDF文件下载后,可能会被浏览器默认打开,此种情况可以点击浏览器菜单,保存网页到桌面,就可以正常下载了。
    3、本站不支持迅雷下载,请使用电脑自带的IE浏览器,或者360浏览器、谷歌浏览器下载即可。
    4、本站资源下载后的文档和图纸-无水印,预览文档经过压缩,下载后原文更清晰。
    5、试题试卷类文档,如果标题没有明确说明有答案则都视为没有答案,请知晓。

    ASTM E2474-2006 Standard Practice for Pharmaceutical Process Design Utilizing Process Analytical Technology《利用过程分析技术进行制药过程设计的标准规程》.pdf

    1、Designation: E 2474 06Standard Practice forPharmaceutical Process Design Utilizing Process AnalyticalTechnology1This standard is issued under the fixed designation E 2474; the number immediately following the designation indicates the year oforiginal adoption or, in the case of revision, the year of

    2、 last revision. A number in parentheses indicates the year of last reapproval. Asuperscript epsilon (e) indicates an editorial change since the last revision or reapproval.INTRODUCTIONProcess design is the systematic conversion of information about needs for a product intoknowledge about how to manu

    3、facture this product. Products and manufacturing processes should bedesigned using science- and risk-based design strategies to manage variation.To attain this goal, integration of Process Analytical Technology (PAT) principles and tools duringprocess design will enhance opportunities to build, main

    4、tain, and expand science- and risk-basedprocess understanding throughout a product lifecycle. The product lifecycle includes the period inproduction as well as development.Process understanding will be the foundation to establish manufacturing (process selection,methodology, implementation, and prac

    5、tice), process control (real-time control on the basis ofmeasured critical quality attributes), effective risk mitigation, and product release concepts.Process understanding will also enable regulatory strategies in that the level of regulatory scrutinymay reflect the demonstrated level of science-

    6、and risk-based process understanding.1. Scope1.1 This practice covers process design, which is integral toprocess development as well as post-development processoptimization. It is focused on practical implementation andexperimental development of process understanding.1.2 The term process design as

    7、 used in this practice canmean:1.2.1 The activities to design a process (the process design),and/or1.2.2 The outcome of this activity (the designed process).1.3 The principles in this practice are applicable to bothdrug substance and drug product processes. For drug products,formulation development

    8、and process development are inter-related and therefore the process design will incorporateknowledge from the formulation development.1.4 The principles in this practice apply during developmentof a new process or the improvement or redesign of an existingone, or both.1.5 This standard does not purp

    9、ort to address all of thesafety concerns, if any, associated with its use. It is theresponsibility of the user of this standard to establish appro-priate safety and health practices and determine the applica-bility of regulatory limitations prior to use.2. Referenced Documents2.1 Referenced Standard

    10、s:FDA Guidance for Industry: PATA Framework for Inno-vative Pharmaceutical Development, Manufacturing, andQuality Assurance, September 20042ICH Guidance: ICH Q8 Pharmaceutical Development, Step4 Document, November 20053ICH Guidance: ICH Q9 Quality Risk Management, Step 4Document, November 200533. PA

    11、T Process Design Practices3.1 Desired StateIn the desired state of a process, allsources of variation are defined and controlled, and endproduct variation is minimal. That implies that critical productattributes are controlled to target for all individual units of aproduct. As a result, processes ar

    12、e capable of consistentlysupplying, unit to unit and batch to batch, the desired quality.Philosophy and Principles3.2 Practice #1: Risk Assessment and MitigationProductsand manufacturing processes should be designed to minimize1This practice is under the jurisdiction of ASTM Committee E55 on Pharma-

    13、ceutical Application of Process Analytical Technology and is the direct responsi-bility of Subcommittee E55.02 on PAT System Implementation desired state; manufacturing; PAT; phar-maceutical process design; process analytical technology; pro-cess understanding; quality risk managementASTM Internatio

    14、nal takes no position respecting the validity of any patent rights asserted in connection with any item mentionedin this standard. Users of this standard are expressly advised that determination of the validity of any such patent rights, and the riskof infringement of such rights, are entirely their

    15、 own responsibility.This standard is subject to revision at any time by the responsible technical committee and must be reviewed every five years andif not revised, either reapproved or withdrawn. Your comments are invited either for revision of this standard or for additional standardsand should be

    16、 addressed to ASTM International Headquarters. Your comments will receive careful consideration at a meeting of theresponsible technical committee, which you may attend. If you feel that your comments have not received a fair hearing you shouldmake your views known to the ASTM Committee on Standards

    17、, at the address shown below.This standard is copyrighted by ASTM International, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA 19428-2959,United States. Individual reprints (single or multiple copies) of this standard may be obtained by contacting ASTM at the aboveaddress or at 610-832-9585 (phone), 610-832-9555 (fax), or serviceastm.org (e-mail); or through the ASTM website(www.astm.org).E2474063


    注意事项

    本文(ASTM E2474-2006 Standard Practice for Pharmaceutical Process Design Utilizing Process Analytical Technology《利用过程分析技术进行制药过程设计的标准规程》.pdf)为本站会员(testyield361)主动上传,麦多课文档分享仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知麦多课文档分享(点击联系客服),我们立即给予删除!




    关于我们 - 网站声明 - 网站地图 - 资源地图 - 友情链接 - 网站客服 - 联系我们

    copyright@ 2008-2019 麦多课文库(www.mydoc123.com)网站版权所有
    备案/许可证编号:苏ICP备17064731号-1 

    收起
    展开